HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sharpless On FDA's Dietary Supplement Regulation Reform: It's 'Complicated'

Executive Summary

"I look forward to beginning a productive dialogue about reshaping our oversight of these products," acting FDA Commissioner Norman Sharpless said recently about agency's public meeting on May 16. Access to meeting at CFSAN headquarters opens at 8 a.m. and irst of four sessions on questions center stated in meeting notice begins at 9 a.m. Each discussion followed by question and answer sessions and public comments scheduled for 3 p.m.

Advertisement

Related Content

Acting FDA Chief Sharpless Pledges 'Full Speed Ahead' On Current Agenda
NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA
DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
FDA Could Stick With Current Advice On NDI Notifications, Old Ingredient Evidence

Topics

Advertisement
UsernamePublicRestriction

Register

RS148808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel